Asset Details
Do you wish to reserve the book?
The human ion channel TRPM2 modulates cell survival in neuroblastoma through E2F1 and FOXM1
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The human ion channel TRPM2 modulates cell survival in neuroblastoma through E2F1 and FOXM1
Do you wish to request the book?
The human ion channel TRPM2 modulates cell survival in neuroblastoma through E2F1 and FOXM1
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The human ion channel TRPM2 modulates cell survival in neuroblastoma through E2F1 and FOXM1
2022
Overview
Transient receptor potential channel melastatin 2 (TRPM2) is highly expressed in cancer and has an essential function in preserving viability through maintenance of mitochondrial function and antioxidant response. Here, the role of TRPM2 in cell survival was examined in neuroblastoma cells with TRPM2 deletion with CRISPR technology. Viability was significantly decreased in TRPM2 knockout after doxorubicin treatment. RNA sequence analysis and RT-qPCR revealed reduced RNAs encoding master transcription regulators FOXM1 and E2F1/2 and downstream cell cycle targets including Cyclin B1, CDK1, PLK1, and CKS1. CHIP analysis demonstrated decreased FOXM1 binding to their promoters. Western blotting confirmed decreased expression, and increased expression of CDK inhibitor p21, a CKS1 target. In cells with TRPM2 deletion, cell cycle progression to S and G2/M phases was reduced after treatment with doxorubicin. RNA sequencing also identified decreased DNA repair proteins in cells with TRPM2 deletion after doxorubicin treatment, and DNA damage was increased. Wild type TRPM2, but not Ca
2+
-impermeable mutant E960D, restored live cell number and reconstituted expression of E2F1, FOXM1, and cell cycle/DNA repair proteins. FOXM1 expression alone restored viability. TRPM2 is a potential therapeutic target to reduce tumor proliferation and increase doxorubicin sensitivity through modulation of FOXM1, E2F1, and cell cycle/DNA repair proteins.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 631/80
/ 692/4028
/ Cell Survival - drug effects
/ CRISPR
/ DNA
/ E2F1 Transcription Factor - metabolism
/ Forkhead Box Protein M1 - genetics
/ Forkhead Box Protein M1 - metabolism
/ Humanities and Social Sciences
/ Humans
/ Neuroblastoma - drug therapy
/ Proteins
/ Science
/ Transient receptor potential proteins
/ TRPM Cation Channels - metabolism
/ Tumors
